

Notification:	HUM 7657
<u>Category:</u>	HCPCS - Drugs & Biologicals
<u>Topic:</u>	Louisiana Medicaid: HCPCS codes J1745, Q5103, Q5104, Q5109 and
	Q5121 – infliximab and its biosimilars
What is changing? /	For providers with a specialty of pharmacy, we limit reimbursement
Change Description:	of charges for HCPCS codes J1745, Q5103, Q5104, Q5109 or Q5121 if
	billed with a diagnosis of juvenile idiopathic arthritis to no more than
	2,522 units every 26 weeks for patients ages 16–18.
Why is Humana making this change?	The limitations above are established by the FDA-approved package
/ Change Reason:	insert and prescribing information and the pharmaceutical
	compendia.
	Note: The limitations described above are based on maximum
	dosages established in milligrams. If any units are denied, the
	provider may dispute the decision through the appropriate process.
	The provider may submit information, including medical notes
	showing the patient's body weight, that substantiates the medical
	necessity of the additional units.
<u>Language:</u>	<u>English</u>
Impacted Products:	Medicaid- Louisiana